GenEditBio

Executive Summary

GenEditBio is a preclinical-stage Chinese gene editing company leveraging CRISPR and other technologies to develop transformative therapies for genetic disorders. Founded in 2019 and based in Suzhou, the company focuses on creating precise, safe, and deliverable editing tools to correct disease-causing mutations. With a lean team of 1-50 employees, GenEditBio aims to advance treatments from concept to clinic for patients with high unmet needs. While still in early stages, the company's focus on in vivo delivery and cutting-edge editing platforms positions it within China's rapidly growing gene therapy landscape. The success of its programs will depend on preclinical proof-of-concept, manufacturing scalability, and regulatory pathways in China and globally.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing40% success
• Q3 2026Preclinical Efficacy Data Readout in Animal Models70% success
• H1 2027Strategic Partnership or Licensing Deal50% success